What the trials and labels say so far
The SUSTAIN-6 trial, published in the New England Journal of Medicine in 2016, tested semaglutide in adults with type 2 diabetes at high cardiovascular risk. Diabetic retinopathy complications were reported more often in the semaglutide group than in the placebo group. The increase was concentrated in participants who already had retinopathy when they enrolled, so existing eye disease deserves closer monitoring.
Safety monitoring after a medicine reaches the market works differently. Pharmacovigilance picks up rare signals that smaller trials can't detect, so a rare side effect can still be real. European regulators reviewed NAION in relation to semaglutide, and the European product information now lists it as a very rare side effect. Product information gets revised, so open the EMA's Ozempic page and check the version and date for the current wording.
Brazilian labels get revised too. The Anvisa bulário is where you find the current bula for Ozempic, Wegovy and Mounjaro, along with what each one says about visual changes and retinopathy. Note the date you consulted it. A dated note is a simple habit, and OzemPro can help you keep notes like that in one place, though the bula itself remains the source.